JP2019514373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514373A5 JP2019514373A5 JP2018555522A JP2018555522A JP2019514373A5 JP 2019514373 A5 JP2019514373 A5 JP 2019514373A5 JP 2018555522 A JP2018555522 A JP 2018555522A JP 2018555522 A JP2018555522 A JP 2018555522A JP 2019514373 A5 JP2019514373 A5 JP 2019514373A5
- Authority
- JP
- Japan
- Prior art keywords
- envelope glycoprotein
- retrovirus
- virus
- fusion protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 41
- 230000008685 targeting Effects 0.000 claims 36
- 239000002245 particle Substances 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 34
- 108020001507 fusion proteins Proteins 0.000 claims 33
- 102000037865 fusion proteins Human genes 0.000 claims 33
- 108090000623 proteins and genes Proteins 0.000 claims 32
- 241001430294 unidentified retrovirus Species 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 29
- 101710126503 Envelope glycoprotein G Proteins 0.000 claims 25
- 241000700605 Viruses Species 0.000 claims 23
- 241000711504 Paramyxoviridae Species 0.000 claims 18
- 241000035314 Henipavirus Species 0.000 claims 15
- 101710126504 Envelope glycoprotein H Proteins 0.000 claims 14
- 102100021696 Syncytin-1 Human genes 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 8
- 230000001086 cytosolic effect Effects 0.000 claims 8
- 102000003886 Glycoproteins Human genes 0.000 claims 7
- 108090000288 Glycoproteins Proteins 0.000 claims 7
- 108010046722 Thrombospondin 1 Proteins 0.000 claims 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 7
- 241000526636 Nipah henipavirus Species 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 230000001177 retroviral effect Effects 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 241000893570 Hendra henipavirus Species 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 108091052347 Glucose transporter family Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 241000712045 Morbillivirus Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 210000004241 Th2 cell Anatomy 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 239000002771 cell marker Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148499A JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305468.7A EP3235908A1 (en) | 2016-04-21 | 2016-04-21 | Methods for selectively modulating the activity of distinct subtypes of cells |
| EP16305468.7 | 2016-04-21 | ||
| PCT/EP2017/059435 WO2017182585A1 (en) | 2016-04-21 | 2017-04-20 | Methods for selectively modulating the activity of distinct subtypes of cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148499A Division JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Division JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514373A JP2019514373A (ja) | 2019-06-06 |
| JP2019514373A5 true JP2019514373A5 (enExample) | 2020-06-11 |
| JP7412885B2 JP7412885B2 (ja) | 2024-01-15 |
Family
ID=56008561
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555522A Active JP7412885B2 (ja) | 2016-04-21 | 2017-04-20 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2021148499A Active JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Pending JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A Active JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A Pending JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148499A Active JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Pending JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A Active JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A Pending JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11608509B2 (enExample) |
| EP (3) | EP3235908A1 (enExample) |
| JP (5) | JP7412885B2 (enExample) |
| KR (2) | KR102775926B1 (enExample) |
| CN (2) | CN117126817A (enExample) |
| AU (3) | AU2017253364B2 (enExample) |
| CA (1) | CA3021549A1 (enExample) |
| EA (1) | EA201892369A1 (enExample) |
| ES (1) | ES2961976T3 (enExample) |
| IL (2) | IL262458B2 (enExample) |
| MX (2) | MX2018012814A (enExample) |
| SG (1) | SG11201809164TA (enExample) |
| WO (1) | WO2017182585A1 (enExample) |
| ZA (1) | ZA201807161B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20250021608A (ko) | 2017-05-08 | 2025-02-13 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 융합을 촉진시키기 위한 조성물 및 그의 용도 |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| MX2020012295A (es) * | 2018-05-15 | 2021-03-31 | Flagship Pioneering Innovations V Inc | Composiciones de fusosoma y usos de estas. |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| KR20210043574A (ko) | 2018-07-09 | 2021-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 푸소좀 조성물 및 이의 용도 |
| EP3880832A1 (en) * | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| AU2019378881A1 (en) * | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for CNS delivery |
| US20230043255A1 (en) * | 2018-11-14 | 2023-02-09 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| JP2022513040A (ja) | 2018-11-14 | 2022-02-07 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | コンパートメント特異的カーゴ送達のための組成物および方法 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| CN110004181B (zh) * | 2019-03-20 | 2022-10-11 | 东北农业大学 | 一种附加型CRISPR/Cas9表达载体及其构建方法与应用 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CA3140115A1 (en) | 2019-05-23 | 2020-11-26 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| EP4034088A4 (en) | 2019-09-26 | 2023-10-11 | President and Fellows of Harvard College | Minimal arrestin domain containing protein 1 (arrdc1) constructs |
| CN110904116B (zh) * | 2019-10-24 | 2022-12-09 | 中国科学院遗传与发育生物学研究所 | 植物phl3基因在调控植物种子大小、干重和脂肪酸积累中的应用 |
| CN115485289A (zh) * | 2020-03-11 | 2022-12-16 | 宾夕法尼亚大学董事会 | 使用工程化的病毒颗粒进行基因递送的方法和组合物 |
| KR20230006819A (ko) * | 2020-03-31 | 2023-01-11 | 사나 바이오테크놀로지, 인크. | 표적화된 지질 입자 및 이의 조성물 및 용도 |
| EP4182447A4 (en) * | 2020-07-14 | 2024-10-23 | Ichilov Tech Ltd. | PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| EP3964585A1 (en) * | 2020-09-03 | 2022-03-09 | Miltenyi Biotec B.V. & Co. KG | Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets |
| TW202242121A (zh) * | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
| IL305411A (en) | 2021-02-26 | 2023-10-01 | Kelonia Therapeutics Inc | Lymphocyte-targeted lentiviral vectors |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| US11535869B2 (en) * | 2021-04-08 | 2022-12-27 | Sana Biotechnology, Inc. | CD8-specific antibody constructs and compositions thereof |
| US20240254168A1 (en) | 2021-05-28 | 2024-08-01 | Sana Biotechnology, Inc. | LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USES |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| WO2023114698A2 (en) * | 2021-12-13 | 2023-06-22 | Interius Biotherapeutics, Inc. | Engineered viral particles and uses of the same |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| EP4448549A2 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4473097A1 (en) | 2022-02-02 | 2024-12-11 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| EP4493157A2 (en) * | 2022-03-11 | 2025-01-22 | President and Fellows of Harvard College | Targeted delivery of armms |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| JPWO2023210616A1 (enExample) * | 2022-04-25 | 2023-11-02 | ||
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| EP4698665A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2024254346A1 (en) * | 2023-06-07 | 2024-12-12 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| CN116515865B (zh) * | 2023-06-19 | 2025-11-14 | 中国人民解放军军事科学院军事医学研究院 | 一种以人复制缺陷腺病毒为载体的尼帕病毒病疫苗 |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US20250101122A1 (en) | 2023-09-25 | 2025-03-27 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| WO2025176853A1 (en) * | 2024-02-22 | 2025-08-28 | Miltenyi Biotec B.V. & Co. KG | Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| CN118108809B (zh) * | 2024-03-15 | 2025-02-28 | 西湖实验室(生命科学和生物医学浙江省实验室) | 一种跨膜荧光蛋白、水溶荧光蛋白及其用途 |
| KR102900650B1 (ko) * | 2024-08-01 | 2025-12-19 | 대한민국 | 니파바이러스 g 당단백질 유래 에피토프를 포함하는 펩타이드 및 이를 포함하는 백신 조성물 |
| CN120209100B (zh) * | 2025-03-28 | 2025-09-05 | 河北金要生物科技有限公司 | 一种表达mIL21和4-1BBL的病毒样颗粒及其在体外扩增NK细胞中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69938931D1 (de) | 1998-09-23 | 2008-07-31 | Inst Virologie Teilrechtsfaehi | Retrovirale partikel, geschützt gegen komplementvermittelte lyse |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| US20020150556A1 (en) | 2000-03-31 | 2002-10-17 | Vile Richard G. | Compositions and methods for tissue specific gene regulation therapy |
| JP2005507927A (ja) | 2001-10-30 | 2005-03-24 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | パーキンソン病を処置するための方法および組成物 |
| WO2003093417A2 (en) | 2002-05-01 | 2003-11-13 | Cell Genesys, Inc. | Lentiviral vector particles resistant to complement inactivation |
| US20060045910A1 (en) | 2004-09-02 | 2006-03-02 | Ehringer William D | Preserved fusogenic vesicles |
| GB0426641D0 (en) | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| JP2008528485A (ja) | 2005-01-20 | 2008-07-31 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 末梢ニューロンへの核酸の送達方法 |
| WO2006115843A2 (en) * | 2005-04-25 | 2006-11-02 | Merial Limited | Nipah virus vaccines |
| WO2007005244A1 (en) | 2005-07-05 | 2007-01-11 | The Regents Of The University Of California | Henipavirus receptor and uses thereof |
| WO2008115199A2 (en) | 2006-08-18 | 2008-09-25 | The University Of North Carolina At Chapel Hill | Chimeric virus vaccines |
| EP1975239A1 (en) * | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| WO2008071959A1 (en) | 2006-12-12 | 2008-06-19 | Oxford Biomedica (Uk) Limited | Lentiviral vectors comprising micrornas |
| DK2282764T3 (da) | 2008-04-22 | 2019-10-14 | Vib Vzw | Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf |
| WO2010053489A1 (en) | 2008-11-07 | 2010-05-14 | Children's Hospital Medical Center | Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems |
| HRP20140327T4 (hr) | 2009-07-24 | 2017-11-03 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis |
| US8697439B2 (en) | 2009-11-13 | 2014-04-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Direct protein delivery with engineered microvesicles |
| EP2476754A1 (en) | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| CN103687590A (zh) | 2011-04-28 | 2014-03-26 | Stc·Unm公司 | 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 |
| UA114086C2 (xx) * | 2011-05-13 | 2017-04-25 | Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah | |
| WO2013056132A2 (en) * | 2011-10-14 | 2013-04-18 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP2615176A1 (en) * | 2012-01-11 | 2013-07-17 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells |
| EP3971286A3 (en) | 2012-03-26 | 2022-04-20 | The Regents of the University of California | Nipah virus envelope pseudotyped lentiviruses and methods of use |
| JP6391582B2 (ja) | 2012-11-13 | 2018-09-19 | コディアック バイオサイエンシズ インコーポレイテッド | 治療剤の送達方法 |
| AU2014249243C1 (en) | 2013-03-13 | 2019-08-08 | Imaginab, Inc. | Antigen binding constructs to CD8 |
| GB201313249D0 (en) | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
| CA2936514C (en) | 2014-01-21 | 2023-08-08 | Joel DE BEER | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
| GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| AU2016217906B2 (en) * | 2015-02-11 | 2021-09-02 | Alma Mater Studiorum Universita' Di Bologna | Retargeted herpesvirus with a glycoprotein H fusion |
| WO2016138525A1 (en) | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| US10729789B2 (en) | 2016-03-01 | 2020-08-04 | University Of Virginia Patent Foundation | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells |
| WO2018009923A1 (en) | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| SG11201807286WA (en) * | 2016-03-19 | 2018-10-30 | F1 Oncology Inc | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| US11458097B2 (en) | 2016-03-30 | 2022-10-04 | The University Of North Carolina At Chapel Hill | Biological agent-exosome compositions and uses thereof |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| KR20190043520A (ko) | 2016-06-09 | 2019-04-26 | 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 | 세포내 번식을 위해 변형된 당단백질 h를 갖는 헤르페스 바이러스 |
| WO2018022747A1 (en) | 2016-07-26 | 2018-02-01 | Senti Biosciences, Inc. | Genetic erasers |
| WO2018129563A1 (en) | 2017-01-09 | 2018-07-12 | Oisin Biotechnologies | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
| KR20250021608A (ko) | 2017-05-08 | 2025-02-13 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 융합을 촉진시키기 위한 조성물 및 그의 용도 |
| CN111655292A (zh) | 2017-12-07 | 2020-09-11 | 旗舰先锋创新V股份有限公司 | 细胞生物制品及其治疗用途 |
| SG11202007114VA (en) | 2018-02-01 | 2020-08-28 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii |
| WO2019161281A1 (en) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| MX2020012295A (es) | 2018-05-15 | 2021-03-31 | Flagship Pioneering Innovations V Inc | Composiciones de fusosoma y usos de estas. |
| KR20210043574A (ko) | 2018-07-09 | 2021-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 푸소좀 조성물 및 이의 용도 |
| US20230043255A1 (en) | 2018-11-14 | 2023-02-09 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| JP2022513040A (ja) | 2018-11-14 | 2022-02-07 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | コンパートメント特異的カーゴ送達のための組成物および方法 |
| AU2019378881A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for CNS delivery |
| EP3880832A1 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
-
2016
- 2016-04-21 EP EP16305468.7A patent/EP3235908A1/en not_active Withdrawn
-
2017
- 2017-04-20 AU AU2017253364A patent/AU2017253364B2/en active Active
- 2017-04-20 EP EP22194343.4A patent/EP4151737A1/en active Pending
- 2017-04-20 IL IL262458A patent/IL262458B2/en unknown
- 2017-04-20 CN CN202311091685.0A patent/CN117126817A/zh active Pending
- 2017-04-20 EP EP17720053.2A patent/EP3445862B1/en active Active
- 2017-04-20 CA CA3021549A patent/CA3021549A1/en active Pending
- 2017-04-20 WO PCT/EP2017/059435 patent/WO2017182585A1/en not_active Ceased
- 2017-04-20 MX MX2018012814A patent/MX2018012814A/es unknown
- 2017-04-20 CN CN201780039032.4A patent/CN109642243A/zh active Pending
- 2017-04-20 US US16/094,636 patent/US11608509B2/en active Active
- 2017-04-20 KR KR1020187033628A patent/KR102775926B1/ko active Active
- 2017-04-20 ES ES17720053T patent/ES2961976T3/es active Active
- 2017-04-20 KR KR1020257006420A patent/KR20250035028A/ko active Pending
- 2017-04-20 SG SG11201809164TA patent/SG11201809164TA/en unknown
- 2017-04-20 EA EA201892369A patent/EA201892369A1/ru unknown
- 2017-04-20 JP JP2018555522A patent/JP7412885B2/ja active Active
-
2018
- 2018-10-19 MX MX2023006961A patent/MX2023006961A/es unknown
- 2018-10-26 ZA ZA2018/07161A patent/ZA201807161B/en unknown
-
2020
- 2020-06-10 AU AU2020203813A patent/AU2020203813B2/en active Active
-
2021
- 2021-09-13 JP JP2021148499A patent/JP7577039B2/ja active Active
-
2022
- 2022-04-08 JP JP2022064496A patent/JP2022087199A/ja active Pending
-
2023
- 2023-03-06 US US18/179,269 patent/US20230348934A1/en active Pending
- 2023-10-31 AU AU2023258359A patent/AU2023258359A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000186A patent/JP7754959B2/ja active Active
-
2025
- 2025-06-19 IL IL321626A patent/IL321626A/en unknown
- 2025-10-02 JP JP2025166535A patent/JP2025188096A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514373A5 (enExample) | ||
| JP2022087199A (ja) | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 | |
| US20260048139A1 (en) | Therapeutic agents comprising nucleic acids and car-modified immune cells, and uses thereof | |
| Shimizu et al. | Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction | |
| CN111743923B (zh) | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 | |
| CN115838439B (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 | |
| JP7680032B2 (ja) | Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 | |
| CN108884440A (zh) | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 | |
| WO2019096115A1 (zh) | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 | |
| US20220096549A1 (en) | Chimeric cytokine receptors | |
| US20250144211A1 (en) | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding | |
| US20240066127A1 (en) | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20230348561A1 (en) | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof | |
| CN118108856A (zh) | 靶向cd5分子的嵌合抗原受体nk细胞及其抗肿瘤应用 | |
| CN116254230A (zh) | 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途 | |
| JP2023545413A (ja) | Ｔ細胞受容体、ｔ細胞受容体を含む免疫細胞およびそれを用いる方法｛ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ、ｉｍｍｕｎｅ ｃｅｌｌ ｃｏｍｐｒｉｓｉｎｇ ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ ａｎｄ ｍｅｔｈｏｄ ｕｓｉｎｇ ｔｈｅ ｓａｍｅ｝ | |
| US20260028388A1 (en) | Recombinant cytokine receptors and methods of use | |
| US20250333697A1 (en) | Tethered interleukin-2 recombinant receptors and methods of use | |
| US20230212257A1 (en) | Anti-cd171 chimeric antigen receptors | |
| AU2024310260A1 (en) | Synthetic cytokine receptors | |
| WO2025034618A1 (en) | A novel t-cell receptor and uses thereof | |
| NZ747658B2 (en) | Methods for selectively modulating the activity of distinct subtypes of cells | |
| Otsuki et al. | 989. Induction of Antitumor Immunity by Cell-Penetrating Peptide-Coupled Hsp70 Gene Transfer to Tumor Cells |